Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women

    Summary
    EudraCT number
    		 2020-004908-33
    Trial protocol
    		 AT   IT   HU   NL   GR  
    Global end of trial date
    27 Nov 2023

    Results information
    Results version number
    		 v1(current)
    This version publication date
    07 Dec 2024
    First version publication date
    07 Dec 2024
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    BAY3427080/21651
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT05042362
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Bayer AG
    Sponsor organisation address
    Kaiser Wilhelm Allee, Leverkusen, Germany, ​D-51368
    Public contact
    Therapeutic Area Head, Bayer AG, +49 30 300139003, clinical-trials-contact@bayer.com
    Scientific contact
    Therapeutic Area Head, Bayer AG, +49 30 300139003, clinical-trials-contact@bayer.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    20 Dec 2023
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    27 Nov 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of this study was to evaluate the efficacy of elinzanetant for the treatment of Vasomotor symptoms (VMS) associated with the menopause.
    Protection of trial subjects
    The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and the International Council for Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent was read by and explained to all the subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    27 Aug 2021
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Austria: 27
    Country: Number of subjects enrolled
    Czechia: 67
    Country: Number of subjects enrolled
    Greece: 6
    Country: Number of subjects enrolled
    Hungary: 21
    Country: Number of subjects enrolled
    Israel: 2
    Country: Number of subjects enrolled
    Italy: 23
    Country: Number of subjects enrolled
    Netherlands: 15
    Country: Number of subjects enrolled
    United States: 235
    Worldwide total number of subjects
    396
    EEA total number of subjects
    159
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    390
    From 65 to 84 years
    6
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 Study was conducted at 89 study centers in 8 countries, between 27-Aug-2021 (first subject first visit) and 27-Nov-2023 (last subject last visit).

    Pre-assignment
    Screening details
    		 A total of 1535 subjects were screened; 1139 subjects were not randomized. Most common reason for not being randomized was not meeting the eligibility criteria (1087 subjects). 396 subjects were randomized to treatment. A total of 197 subjects were randomized to placebo-elinzanetant 120 mg arm and 199 subjects to elinzanetant 120 mg arm.

    Period 1
    Period 1 title
    Overall study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator, Monitor, Carer, Data analyst, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Elinzanetant 120 mg
    Arm description
    		 Subjects received elinzanetant 120 mg orally once daily for 26 weeks.
    Arm type
    		 Experimental

    Investigational medicinal product name
    Elinzanetant
    Investigational medicinal product code
    BAY3427080
    Other name
    NT-814
    Pharmaceutical forms
    Capsule, soft
    Routes of administration
    Oral use
    Dosage and administration details
    Two capsules of 60 mg elinzanetant once daily in the evening before bedtime for 26 weeks.

    Arm title
    		 Placebo - Elinzanetant 120 mg
    Arm description
    		 Subjects received placebo for 12 weeks, followed by elinzanetant 120 mg orally once daily for 14 weeks
    Arm type
    		 Experimental

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, soft
    Routes of administration
    Oral use
    Dosage and administration details
    Two capsules once daily in the evening before bedtime from week 1 to week 12.

    Investigational medicinal product name
    Elinzanetant
    Investigational medicinal product code
    BAY3427080
    Other name
    NT-814
    Pharmaceutical forms
    Capsule, soft
    Routes of administration
    Oral use
    Dosage and administration details
    Two capsules of 60 mg elinzanetant once daily in the evening before bedtime from week 13 to week 26.

    Number of subjects in period 1
    		Elinzanetant 120 mg Placebo - Elinzanetant 120 mg
    Started
    199
    197
    Completed
    154
    155
    Not completed
    45
    42
         Consent withdrawn by subject
    5
    9
         Physician decision
    3
    -
         Randomized by Mistake
    1
    2
         Non-Compliance with Study Drug
    2
    3
         Adverse event, non-fatal
    7
    9
         Other
    -
    1
         Did not complete study treatment but completed FU
    16
    10
         Lost to follow-up
    7
    4
         Missing
    4
    2
         Lack of efficacy
    -
    2

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Elinzanetant 120 mg
    Reporting group description
    		 Subjects received elinzanetant 120 mg orally once daily for 26 weeks.

    Reporting group title
    Placebo - Elinzanetant 120 mg
    Reporting group description
    		 Subjects received placebo for 12 weeks, followed by elinzanetant 120 mg orally once daily for 14 weeks

    Reporting group values
    		 Elinzanetant 120 mg Placebo - Elinzanetant 120 mg Total
    Number of subjects
    		 199 197 396
    Age Categorical
    Units: Subjects
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    		 54.6 ( 4.9 ) 54.5 ( 4.9 ) -
    Gender Categorical
    Units: Subjects
        Female
    		 199 197 396
        Male
    		 0 0 0
    Race
    Units: Subjects
        White
    		 151 154 305
        Black or African American
    		 38 38 76
        Asian
    		 2 1 3
        American Indian or Alaska Native
    		 1 1 2
        Multiple
    		 3 0 3
        Other
    		 4 3 7
    Ethnicity
    Units: Subjects
        Not Hispanic or Latino
    		 180 179 359
        Hispanic or Latino
    		 17 14 31
        Other
    		 2 4 6
    Mean frequency of moderate to severe hot flash (HF) at baseline
    Subjects’ assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and night. Mild HF was defined as a “sensation of heat without sweating”, moderate HF was defined as a “sensation of heat with sweating, but able to continue activity”, severe HF was defined as a “sensation of heat with sweating, causing cessation (stopping) of activity”. The number of analyzed subjects was 199 for elinzanetant 120 mg, 197 for placebo - elinzanetant 120 mg.
    Units: Hot Flashes per day
        arithmetic mean (standard deviation)
    		 13.38 ( 6.57 ) 14.26 ( 13.94 ) -
    Mean severity of moderate to severe HF at baseline
    The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF are defined as a “sensation of heat without sweating”, moderate HF are defined as a “sensation of heat with sweating, but able to continue activity”, and severe HF are defined as a “sensation of heat with sweating, causing cessation (stopping) of activity”. The number of analyzed subjects was 199 for elinzanetant 120 mg and 197 for placebo - elinzanetant 120 mg.
    Units: Severity scale
        arithmetic mean (standard deviation)
    		 2.56 ( 0.22 ) 2.53 ( 0.23 ) -
    PROMIS SD SF 8b total T-score at baseline
    The PROMIS SD SF 8b included 8 items assessing sleep disturbance over the past 7 days. Items assessed sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. The number of analyzed subjects was 184 for elinzanetant 120 mg and 179 for placebo - elinzanetant 120 mg.
    Units: Scores on scale
        arithmetic mean (standard deviation)
    		 61.0 ( 7.7 ) 60.2 ( 7.2 ) -
    Menopause-specific quality of life scale (MENQOL) total score at baseline
    The MENQOL questionnaire was comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assessed four domains of symptoms and functioning: VMS, psychosocial functioning, physical functioning, and sexual functioning. The number of analyzed subjects was 179 for elinzanetant 120 mg and 173 for placebo - elinzanetant 120 mg.
    Units: Scores on scale
        arithmetic mean (standard deviation)
    		 4.56 ( 1.27 ) 4.49 ( 1.31 ) -
    Beck depression inventory (BDI-II) total score at baseline
    The BDI-II was a 21-item questionnaire assessing the intensity of depressive symptoms over the past 2 weeks. Items used a 4-point verbal response scale ranging from 0 (not at all) to 3 (extreme form of each symptom). A total score ranging from 0 to 63 was calculated with scores of 0-13 indicating mild minimal range, 14 – 19 mild depression, 20 – 28 indicating moderate and 29 – 63 severe depression (higher score = greater depression). The number of analyzed subjects was 199 for elinzanetant 120 mg and 197 for placebo - elinzanetant 120 mg.
    Units: Scores on scale
        arithmetic mean (standard deviation)
    		 6.8 ( 6.5 ) 6.2 ( 6.7 ) -

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Elinzanetant 120 mg
    Reporting group description
    		 Subjects received elinzanetant 120 mg orally once daily for 26 weeks.

    Reporting group title
    Placebo - Elinzanetant 120 mg
    Reporting group description
    		 Subjects received placebo for 12 weeks, followed by elinzanetant 120 mg orally once daily for 14 weeks

    Subject analysis set title
    Safety Analysis Set (SAF)
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    All subjects who received at least one dose of study intervention were analyzed according to the intervention they received.

    Subject analysis set title
    Full Analysis Set (FAS)
    Subject analysis set type
    		 Full analysis
    Subject analysis set description
    All randomized subjects were included. Subjects in the full analysis set were analyzed according to the randomized intervention (intention-to-treat).

    Primary: Mean change in frequency of moderate to severe HF from baseline to Week 4 (assessed by hot flash daily diary [HFDD]).

    		 Close Top of page
    End point title
    		 Mean change in frequency of moderate to severe HF from baseline to Week 4 (assessed by hot flash daily diary [HFDD]).
    End point description
    Subjects recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF were defined as a “sensation of heat without sweating”, moderate HF were defined as a “sensation of heat with sweating, but able to continue activity”, and severe HF were defined as a “sensation of heat with sweating, causing cessation (stopping) of activity”. The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 4 Days 22-28 were used (Day 1 corresponds to start of treatment).
    End point type
    Primary
    End point timeframe
    From baseline to Week 4
    End point values
    		 Elinzanetant 120 mg Placebo - Elinzanetant 120 mg
    Number of subjects analysed
    191 [1]
    185 [2]
    Units: Hot Flashes per day
    arithmetic mean (standard deviation)
        Week 4: Change from baseline
    -7.48 ( 5.80 )
    -4.37 ( 6.73 )
    Notes
    [1] - FAS
    [2] - FAS
    Statistical analysis title
    		 Elinzanetant 120 mg versus placebo
    Statistical analysis description
    The total number of subjects with observed value for this timepoint, who were considered in the analysis model, was 383. This included subjects who prematurely discontinued study drug, and continued in a post-treatment period who were not considered under “number of subjects included in analysis” given below.
    Comparison groups
    Elinzanetant 120 mg v Placebo - Elinzanetant 120 mg
    Number of subjects included in analysis
    376
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001 [3]
    Method
    		 Mixed model repeated measures (MMRM)
    Parameter type
    		 Difference in LS-means
    Point estimate
    -3.29
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -4.47
         upper limit
    		 -2.1
    Notes
    [3] - one-sided

    Primary: Mean change in frequency of moderate to severe HF from baseline to Week 12 (assessed by HFDD).

    		 Close Top of page
    End point title
    		 Mean change in frequency of moderate to severe HF from baseline to Week 12 (assessed by HFDD).
    End point description
    The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 12 Days 78-84 were used (Day 1 corresponds to start of treatment).
    End point type
    Primary
    End point timeframe
    From baseline to Week 12
    End point values
    		 Elinzanetant 120 mg Placebo - Elinzanetant 120 mg
    Number of subjects analysed
    175 [4]
    169 [5]
    Units: Hot Flashes per day
    arithmetic mean (standard deviation)
        Week 12: Change from baseline
    -8.74 ( 6.70 )
    -5.53 ( 10.16 )
    Notes
    [4] - FAS
    [5] - FAS
    Statistical analysis title
    		 Elinzanetant 120 mg versus placebo
    Statistical analysis description
    The total number of subjects with observed value for this timepoint, who were considered in the analysis model, was 353. This included subjects who prematurely discontinued study drug, and continued in a post-treatment period who were not considered under “number of subjects included in analysis” given below.
    Comparison groups
    Elinzanetant 120 mg v Placebo - Elinzanetant 120 mg
    Number of subjects included in analysis
    344
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001 [6]
    Method
    		 MMRM
    Parameter type
    		 Difference in LS-means
    Point estimate
    -3.22
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -4.81
         upper limit
    		 -1.63
    Notes
    [6] - one-sided

    Secondary: Mean change in severity of moderate to severe HF from baseline to Week 4 (assessed by HFDD).

    		 Close Top of page
    End point title
    		 Mean change in severity of moderate to severe HF from baseline to Week 4 (assessed by HFDD).
    End point description
    In the HFDD, the severity of HFs was categorized as: 1 = mild, 2 = moderate, and 3 = severe; therefore, a decrease in severity indicates an improvement. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF were defined as a “sensation of heat without sweating”, moderate HF were defined as a “sensation of heat with sweating, but able to continue activity”, and severe HF were defined as a “sensation of heat with sweating, causing cessation (stopping) of activity”.
    End point type
    Secondary
    End point timeframe
    From baseline to Week 4
    End point values
    		 Elinzanetant 120 mg Placebo - Elinzanetant 120 mg
    Number of subjects analysed
    191 [7]
    185 [8]
    Units: Severity scale
    arithmetic mean (standard deviation)
        Week 4: Change from baseline
    -0.73 ( 0.64 )
    -0.39 ( 0.43 )
    Notes
    [7] - FAS
    [8] - FAS
    Statistical analysis title
    		 Elinzanetant 120 mg versus placebo
    Statistical analysis description
    The total number of subjects with observed value for this timepoint, who were considered in the analysis model, was 383. This included subjects who prematurely discontinued study drug, and continued in a post-treatment period who were not considered under “number of subjects included in analysis” given below.
    Comparison groups
    Elinzanetant 120 mg v Placebo - Elinzanetant 120 mg
    Number of subjects included in analysis
    376
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001 [9]
    Method
    		 MMRM
    Parameter type
    		 Difference in LS-means
    Point estimate
    -0.33
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -0.44
         upper limit
    		 -0.23
    Notes
    [9] - one-sided

    Secondary: Mean change in severity of moderate to severe HF from baseline to Week 12 (assessed by HFDD).

    		 Close Top of page
    End point title
    		 Mean change in severity of moderate to severe HF from baseline to Week 12 (assessed by HFDD).
    End point description
    In the HFDD, the severity of HFs was categorized as: 1 = mild, 2 = moderate, and 3 = severe; therefore, a decrease in the HF severity score indicates an improvement. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF are defined as a “sensation of heat without sweating”, moderate HF are defined as a “sensation of heat with sweating, but able to continue activity”, and severe HF are defined as a “sensation of heat with sweating, causing cessation (stopping) of activity”.
    End point type
    Secondary
    End point timeframe
    From baseline to Week 12
    End point values
    		 Elinzanetant 120 mg Placebo - Elinzanetant 120 mg
    Number of subjects analysed
    175 [10]
    169 [11]
    Units: Severity scale
    arithmetic mean (standard deviation)
        Week 12: Change from baseline
    -0.95 ( 0.78 )
    -0.55 ( 0.60 )
    Notes
    [10] - FAS
    [11] - FAS
    Statistical analysis title
    		 Elinzanetant 120 mg versus placebo
    Statistical analysis description
    The total number of subjects with observed value for this timepoint, who were considered in the analysis model, was 353. This included subjects who prematurely discontinued study drug, and continued in a post-treatment period who were not considered under “number of subjects included in analysis” given below.
    Comparison groups
    Elinzanetant 120 mg v Placebo - Elinzanetant 120 mg
    Number of subjects included in analysis
    344
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001 [12]
    Method
    		 MMRM
    Parameter type
    		 Difference in LS-means
    Point estimate
    -0.4
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -0.54
         upper limit
    		 -0.25
    Notes
    [12] - one-sided

    Secondary: Mean change in frequency of moderate to severe HF from baseline to Week 1 (assessed by HFDD).

    		 Close Top of page
    End point title
    		 Mean change in frequency of moderate to severe HF from baseline to Week 1 (assessed by HFDD).
    End point description
    Subjects’ assessments of HF were recorded electronically twice daily using the sponsor developed HFDD. The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device.
    End point type
    Secondary
    End point timeframe
    From baseline to Week 1
    End point values
    		 Elinzanetant 120 mg Placebo - Elinzanetant 120 mg
    Number of subjects analysed
    196 [13]
    189 [14]
    Units: Hot Flashes per day
    arithmetic mean (standard deviation)
        Week 1: Change from baseline
    -5.00 ( 5.05 )
    -2.72 ( 4.99 )
    Notes
    [13] - FAS
    [14] - FAS
    Statistical analysis title
    		 Elinzanetant 120 mg versus placebo
    Statistical analysis description
    The total number of subjects with observed value for this timepoint, who were considered in the analysis model, was 385. This included subjects who prematurely discontinued study drug, and continued in a post-treatment period who were not considered under “number of subjects included in analysis” given below.
    Comparison groups
    Elinzanetant 120 mg v Placebo - Elinzanetant 120 mg
    Number of subjects included in analysis
    385
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001 [15]
    Method
    		 MMRM
    Parameter type
    		 Difference in LS-means
    Point estimate
    -2.45
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -3.36
         upper limit
    		 -1.55
    Notes
    [15] - one-sided

    Secondary: Mean change in frequency of moderate to severe HF from baseline over time.

    		 Close Top of page
    End point title
    		 Mean change in frequency of moderate to severe HF from baseline over time.
    End point description
    The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 1 Days 2-8 were used instead of 1-7, because the intake started on Day 1 only before going to bed, for Week 4 Days 22-28 were used and for Week 12 Days 78-84 were used (Day 1 corresponds to start of treatment). These data were aggregated to a mean daily frequency as (total number of moderate to severe HF during that week) / (total number of available days with data during that week). In case data was not available for more than 2 days within a week, the value for that particular week was set to missing.
    End point type
    Secondary
    End point timeframe
    From baseline to Week 30
    End point values
    		 Elinzanetant 120 mg Placebo - Elinzanetant 120 mg
    Number of subjects analysed
    199 [16]
    197 [17]
    Units: Hot Flashes per day
    arithmetic mean (standard deviation)
        Week 1 (N=196, 189)
    -5.00 ( 5.05 )
    -2.72 ( 4.99 )
        Week 4 (N=191, 185)
    -7.48 ( 5.8 )
    -4.37 ( 6.73 )
        Week 8 (N=180, 175)
    -8.42 ( 6.5 )
    -5.24 ( 8.08 )
        Week 12 (N=175, 169)
    -8.74 ( 6.7 )
    -5.53 ( 10.16 )
        Week 16 (N=170, 160)
    -9.19 ( 6.21 )
    -8.08 ( 8.87 )
        Week 20 (N=161, 160)
    -9.87 ( 6.40 )
    -8.88 ( 8.30 )
        Week 26 (N=114, 110)
    -10.11 ( 6.41 )
    -10.10 ( 8.75 )
        Week 30 (N=141, 129)
    -6.70 ( 5.99 )
    -6.15 ( 10.52 )
    Notes
    [16] - FAS
    [17] - FAS
    No statistical analyses for this end point

    Secondary: Mean change in Patient-reported outcomes measurement information system sleep disturbance short form 8b (PROMIS SD SF 8b) total T-score from baseline to Week 12.

    		 Close Top of page
    End point title
    		 Mean change in Patient-reported outcomes measurement information system sleep disturbance short form 8b (PROMIS SD SF 8b) total T-score from baseline to Week 12.
    End point description
    The PROMIS SD SF 8b included 8 items assessing sleep disturbance over the past 7 days. Items assessed sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Subjects responded to the items on a 5-point scale from not at all, never or very poor to very much, always or very good. Four of the items were scored reversely. Total scores ranged from 8 to 40, with higher scores indicating greater severity of sleep disturbance. The total scores were converted to total T-scores used for the analysis.
    End point type
    Secondary
    End point timeframe
    From baseline to Week 12
    End point values
    		 Elinzanetant 120 mg Placebo - Elinzanetant 120 mg
    Number of subjects analysed
    166 [18]
    156 [19]
    Units: Scores on scale
    arithmetic mean (standard deviation)
        Week 12: Change from baseline
    -10.8 ( 9.6 )
    -5.0 ( 6.9 )
    Notes
    [18] - FAS
    [19] - FAS
    Statistical analysis title
    		 Elinzanetant 120 mg versus placebo
    Statistical analysis description
    The total number of subjects with observed value for this timepoint, who were considered in the analysis model, was 354. This included subjects who prematurely discontinued study drug, and continued in a post-treatment period who were not considered under “number of subjects included in analysis” given below.
    Comparison groups
    Elinzanetant 120 mg v Placebo - Elinzanetant 120 mg
    Number of subjects included in analysis
    322
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001 [20]
    Method
    		 MMRM
    Parameter type
    		 Difference in LS-means
    Point estimate
    -5.58
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -7.18
         upper limit
    		 -3.98
    Notes
    [20] - one-sided

    Secondary: Mean change in MENQOL total score from baseline to Week 12.

    		 Close Top of page
    End point title
    		 Mean change in MENQOL total score from baseline to Week 12.
    End point description
    The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: VMS, psychosocial functioning, physical functioning, and sexual functioning. For each item, the subject indicates if they have experienced the symptom (yes/no). If subjects select yes, subjects rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother.
    End point type
    Secondary
    End point timeframe
    From baseline to Week 12
    End point values
    		 Elinzanetant 120 mg Placebo - Elinzanetant 120 mg
    Number of subjects analysed
    160 [21]
    152 [22]
    Units: Scores on scale
    arithmetic mean (standard deviation)
        Week 12: Change from baseline
    -1.41 ( 1.30 )
    -0.96 ( 1.11 )
    Notes
    [21] - FAS
    [22] - FAS
    Statistical analysis title
    		 Elinzanetant 120 mg versus placebo
    Statistical analysis description
    The total number of subjects with observed value for this timepoint, who were considered in the analysis model, was 351. This included subjects who prematurely discontinued study drug, and continued in a post-treatment period who were not considered under “number of subjects included in analysis” given below.
    Comparison groups
    Elinzanetant 120 mg v Placebo - Elinzanetant 120 mg
    Number of subjects included in analysis
    312
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001 [23]
    Method
    		 MMRM
    Parameter type
    		 Difference in LS-means
    Point estimate
    -0.42
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -0.64
         upper limit
    		 -0.2
    Notes
    [23] - one-sided

    Secondary: Mean change in BDI-II total score from baseline to Week 12.

    		 Close Top of page
    End point title
    		 Mean change in BDI-II total score from baseline to Week 12.
    End point description
    The BDI-II is a 21-item questionnaire assessing the intensity of depressive symptoms over the past 2 weeks. Each item is a list of four statements arranged in increasing levels of severity about a particular symptom of depression. Items use a 4-point verbal response scale ranging from 0 (not at all) to 3 (extreme form of each symptom); specific response options are tailored to the aspect of depression being measured in each item. A total score ranging from 0 to 63 is calculated with scores of 0-13 indicating mild minimal range, 14 – 19 mild depression, 20 – 28 indicating moderate and 29 – 63 severe depression (higher score = greater depression).
    End point type
    Secondary
    End point timeframe
    From baseline to Week 12
    End point values
    		 Elinzanetant 120 mg Placebo - Elinzanetant 120 mg
    Number of subjects analysed
    175 [24]
    168 [25]
    Units: Scores on scale
    arithmetic mean (standard deviation)
        Week 12: Change from baseline
    -0.5 ( 7.2 )
    0.9 ( 6.5 )
    Notes
    [24] - FAS
    [25] - FAS
    No statistical analyses for this end point

    Secondary: Mean change in BDI-II total score from baseline to Week 26.

    		 Close Top of page
    End point title
    		 Mean change in BDI-II total score from baseline to Week 26.
    End point description
    End point type
    Secondary
    End point timeframe
    From baseline to Week 26
    End point values
    		 Elinzanetant 120 mg Placebo - Elinzanetant 120 mg
    Number of subjects analysed
    108 [26]
    104 [27]
    Units: Scores on scale
    arithmetic mean (standard deviation)
        Week 26: Change from baseline
    -0.9 ( 6.7 )
    -0.6 ( 5.5 )
    Notes
    [26] - FAS
    [27] - FAS
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From the start of study medication up to 14 days after the last dose of medication, approximately 28 weeks.
    Adverse event reporting additional description
    Adverse event reporting for the deaths (all causes) considers all deaths that occurred at any time during the study before the last contact, approximately 30 weeks.
    Assessment type
    		 Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    26.0
    Reporting groups
    Reporting group title
    Elinzanetant 120 mg Week 1-12
    Reporting group description
    		 Subjects who received elinzanetant 120 mg during Weeks 1-12. Reported AEs for the exposure period Weeks 1-12 to elinzanetant.

    Reporting group title
    Placebo Week 1-12
    Reporting group description
    		 Subjects who received placebo during Weeks 1-12. Reported AEs for the exposure period to placebo.

    Reporting group title
    Elinzanetant 120 mg Week 1-26
    Reporting group description
    		 Subjects who received elinzanetant 120 mg at any time during the study (including those who switched from placebo to elinzanetant 120 mg at Week 13). Reported AEs for the exposure period to elinzanetant for both treatment groups.

    Reporting group title
    Placebo - Elinzanetant 120 mg Week 13-26
    Reporting group description
    		 Subjects who received placebo during Weeks 1-12 and switched to elinzanetant 120 mg after Week 12. Reported AEs for the exposure period to elinzanetant.

    Reporting group title
    Elinzanetant 120 mg Week 13-26
    Reporting group description
    		 Subjects who received elinzanetant 120 mg during Weeks 1-12 and continued with elinzanetant 120 mg after Week 12. Reported AEs for the exposure period Weeks 13 - 26 to elinzanetant.

    Serious adverse events
    		 Elinzanetant 120 mg Week 1-12 Placebo Week 1-12 Elinzanetant 120 mg Week 1-26 Placebo - Elinzanetant 120 mg Week 13-26 Elinzanetant 120 mg Week 13-26
    Total subjects affected by serious adverse events
         subjects affected / exposed
    4 / 199 (2.01%)
    2 / 194 (1.03%)
    13 / 367 (3.54%)
    9 / 168 (5.36%)
    0 / 171 (0.00%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    0
    Injury, poisoning and procedural complications
    Accident
         subjects affected / exposed
    0 / 199 (0.00%)
    0 / 194 (0.00%)
    1 / 367 (0.27%)
    1 / 168 (0.60%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tibia fracture
         subjects affected / exposed
    0 / 199 (0.00%)
    0 / 194 (0.00%)
    1 / 367 (0.27%)
    1 / 168 (0.60%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Surgical and medical procedures
    Arthrodesis
         subjects affected / exposed
    1 / 199 (0.50%)
    0 / 194 (0.00%)
    1 / 367 (0.27%)
    0 / 168 (0.00%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bunion operation
         subjects affected / exposed
    0 / 199 (0.00%)
    0 / 194 (0.00%)
    1 / 367 (0.27%)
    1 / 168 (0.60%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mammoplasty
         subjects affected / exposed
    0 / 199 (0.00%)
    0 / 194 (0.00%)
    1 / 367 (0.27%)
    1 / 168 (0.60%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Syncope
         subjects affected / exposed
    1 / 199 (0.50%)
    0 / 194 (0.00%)
    1 / 367 (0.27%)
    0 / 168 (0.00%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    0 / 199 (0.00%)
    0 / 194 (0.00%)
    1 / 367 (0.27%)
    1 / 168 (0.60%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholecystitis acute
         subjects affected / exposed
    0 / 199 (0.00%)
    1 / 194 (0.52%)
    0 / 367 (0.00%)
    0 / 168 (0.00%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    0 / 199 (0.00%)
    1 / 194 (0.52%)
    2 / 367 (0.54%)
    2 / 168 (1.19%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 2
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pulmonary embolism
         subjects affected / exposed
    1 / 199 (0.50%)
    0 / 194 (0.00%)
    1 / 367 (0.27%)
    0 / 168 (0.00%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Diverticulitis
         subjects affected / exposed
    1 / 199 (0.50%)
    0 / 194 (0.00%)
    1 / 367 (0.27%)
    0 / 168 (0.00%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Otitis externa
         subjects affected / exposed
    0 / 199 (0.00%)
    0 / 194 (0.00%)
    1 / 367 (0.27%)
    1 / 168 (0.60%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    1 / 199 (0.50%)
    0 / 194 (0.00%)
    1 / 367 (0.27%)
    0 / 168 (0.00%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    0 / 199 (0.00%)
    0 / 194 (0.00%)
    1 / 367 (0.27%)
    1 / 168 (0.60%)
    0 / 171 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Elinzanetant 120 mg Week 1-12 Placebo Week 1-12 Elinzanetant 120 mg Week 1-26 Placebo - Elinzanetant 120 mg Week 13-26 Elinzanetant 120 mg Week 13-26
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    38 / 199 (19.10%)
    28 / 194 (14.43%)
    51 / 367 (13.90%)
    9 / 168 (5.36%)
    6 / 171 (3.51%)
    Investigations
    Depression rating scale score increased
         subjects affected / exposed
    12 / 199 (6.03%)
    11 / 194 (5.67%)
    14 / 367 (3.81%)
    2 / 168 (1.19%)
    1 / 171 (0.58%)
         occurrences all number
    13
    12
    16
    2
    1
    Nervous system disorders
    Headache
         subjects affected / exposed
    14 / 199 (7.04%)
    5 / 194 (2.58%)
    24 / 367 (6.54%)
    6 / 168 (3.57%)
    4 / 171 (2.34%)
         occurrences all number
    14
    5
    25
    7
    4
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    14 / 199 (7.04%)
    3 / 194 (1.55%)
    15 / 367 (4.09%)
    1 / 168 (0.60%)
    0 / 171 (0.00%)
         occurrences all number
    14
    3
    15
    1
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    10 / 199 (5.03%)
    10 / 194 (5.15%)
    12 / 367 (3.27%)
    1 / 168 (0.60%)
    1 / 171 (0.58%)
         occurrences all number
    10
    11
    12
    1
    1

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    10 Feb 2022
    Changes consist of three types, (i) they addressed comments from authorities (FDA and Portuguese Health Authority) during the initial CTA review process, (ii) helped to clarify certain aspects of the protocol or (iii) they were minor corrections.
    22 Jun 2022
    Changes consist of three types, (i) they addressed comments from FDA, (ii) helped to clarify certain aspects of the protocol or (iii) they were minor corrections.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 14:20:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA